Group 1 - Sichuan Chengyu's wholly-owned subsidiary plans to acquire 85% equity of Hubei Jingyi Company for 2.409 billion yuan, enhancing the company's control over highway projects [1] - Huadian Technology signed contracts worth approximately 815 million yuan with Huadian Technology Group for a wind power hydrogen production project [2] - Dongfang Cable and its subsidiary won projects totaling approximately 3.125 billion yuan, accounting for 34.37% of the company's audited revenue for 2024 [3] Group 2 - Heng Rui Medicine received approval for clinical trials of SHR-2906 injection, a self-developed biopharmaceutical aimed at weight control and metabolic regulation [4] - Qingdao Port plans to invest approximately 15.7 billion yuan in two terminal projects [5] - Jingu Co. received a notification to supply low-carbon wheels for two export models to a major domestic car manufacturer, with production expected in 2026 [6] Group 3 - ST Xingguang won a procurement project worth approximately 22.955 million yuan, accounting for 11.96% of the company's revenue for 2024 [7] - Xinbo Co. plans to jointly invest in an alloy materials research institute with partners, focusing on high-performance materials for various industries [8] - Tianqi Lithium's third-phase lithium concentrate expansion project has been completed and is undergoing trial production, with a total capacity of 2.14 million tons per year [9] Group 4 - Changfei Fiber reported that new fiber optic products related to data centers represent a small proportion of total demand [10] - Dongfang Bio's subsidiaries obtained multiple medical device registration certificates, including various testing kits [11] - Xiugang Co. plans to use up to 500 million yuan of idle fundraising for cash management in safe, liquid investment products [12] Group 5 - Jifeng Co. received a project designation for passenger car seat assemblies from a European luxury brand, with a total lifecycle value of approximately 9.8 billion yuan [13] - CanSino initiated Phase I clinical trials for a combined vaccine, completing the first subject enrollment [14] - Dayu Water-saving's subsidiary pre-won a drainage project worth 140 million yuan and another project worth 1 billion yuan [15] Group 6 - Yutong Pharmaceutical's subsidiary received clinical trial approval for YKYY032 injection for treating hyperlipoproteinemia [17] - Diweier announced the departure of a core technical personnel, impacting its technical leadership [18] - Weilang Co.'s controlling shareholder received regulatory measures from the Shandong Securities Regulatory Bureau for failing to fulfill a commitment [19] Group 7 - Xiehe Electronics invested 5 million yuan in a private equity fund focusing on hard technology sectors [20] - Phoenix Optical received a government subsidy of 4.7053 million yuan, representing 35% of its projected net profit for 2024 [21] - China State Construction reported a 0.9% year-on-year increase in new contracts signed in the first 11 months of 2025, totaling 4.0408 trillion yuan [22] Group 8 - Nanguang Energy's pumped storage power station units 1 and 2 have entered trial operation, with units 3 and 4 expected to follow by year-end [23] - Jindalai plans to invest 280 million yuan to acquire a 34% stake in Yunnan Jici Medical Technology [24] - Geer Software terminated its planned acquisition of a majority stake in Weipin Zhiyuan due to failure to reach agreement on key terms [25] Group 9 - Ningbo Fubang completed the absorption merger of its wholly-owned subsidiary, inheriting all assets and liabilities [26] - Zhongyuan Neipei signed a strategic cooperation framework agreement with Ningbo Puzhi Company for humanoid robot-related business [28] - Gongyuan Co. announced a business integration and relocation of its production lines in the East China region [29] Group 10 - Chlor-alkali Chemical's subsidiary plans to invest 2.975 billion yuan in a comprehensive utilization project for waste salt [30] - Kain Technology announced the departure of a core technical personnel, impacting its research capabilities [31] - ST Renfu received approval for clinical trials of a new drug for idiopathic pulmonary fibrosis [32] Group 11 - Sanbo Brain Science's established brain science fund has completed registration with the Asset Management Association of China [33] - Tongyou Technology plans to apply for a 70 million yuan credit line from Beijing Bank, using its property as collateral [34] - Bai Ao Intelligent signed a significant equipment sales contract worth approximately 27.5021 million yuan [35] Group 12 - ST Xinyan received all restructuring investment funds totaling 2.239 billion yuan, entering the execution phase of its restructuring plan [36] - Dalu Real Estate's subsidiary decided to terminate a planned acquisition of a 60% stake in Beijing Chengzhu Real Estate [38] - Huiyu Pharmaceutical's products received marketing approval in Italy and Norway [39]

每经AI快讯，凤凰光学（SH 600071，收盘价：20.8元）12月19日晚间发布公告称，凤凰光学股份有限 公司下属全资子公司凤凰智能电子（杭州）有限公司于2025年12月19日收到与收益相关的政府补助约 471万元，占公司2024年度经审计归属于上市公司股东净利润的35%。 （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 截至发稿，凤凰光学市值为59亿元。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ ...

Group 1 - The core point of the article is that Phoenix Optical (600071.SH) announced that its wholly-owned subsidiary, Phoenix Intelligent Electronics (Hangzhou) Co., Ltd., received a government subsidy related to revenue amounting to 4.7053 million yuan, which accounts for 35.00% of the company's audited net profit attributable to shareholders for the fiscal year 2024 [1]

一、获得补助的基本情况 凤凰光学股份有限公司(以下简称"公司")下属全资子公司凤凰 智能电子（杭州）有限公司于 2025 年 12 月 19 日收到与收益相关 的政府补助 4,705,293.15元，占公司 2024 年度经审计归属于上市 公司股东净利润的 35.00%。 证券代码：600071 证券简称：凤凰光学 公告编号：2025-036 凤凰光学股份有限公司 获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 特此公告。 凤凰光学股份有限公司董事会 2025 年 12 月 20 日 二、补助的类型及其对上市公司的影响 根据《企业会计准则第 16 号—政府补助》的相关规定，公司确 认上述与收益相关的政府补助4,705,293.15元全额计入其他收益，上 述取得的政府补助将对公司2025年度经营业绩产生积极影响，具体会 计处理须以会计师审计确认后的结果为准，敬请广大投资者注意投资 风险。 ...

凤凰光学股份有限公司 2025 年第三次临时股东会会议资料 凤凰光学股份有限公司 2025年第三次临时股东会 会议资料 1 凤凰光学股份有限公司 2025 年第三次临时股东会会议资料 凤凰光学股份有限公司 2025年第三次临时股东会议程 | 会议名称 | 凤凰光学股份有限公司 | 2025 年第三次临时股东会 | | | --- | --- | --- | --- | | 会议召开 方式 | 现场+网络 | 会议召集人 | 公司董事会 | | 会议时间 | 现场会议时间：2025 年 12 月 22 日 13 点 网络会议时间：2025 年 12 月 22 日上午 | 30 分 9:15 至 12 月 22 | 日下午 15:00 | | 会议地点 | 江西省上饶市凤凰西大道 | 197 号本公司四楼会议室 | | | 会议主持人 | 公司董事 | 会议法律见证 | 上海市方达律师事务所 | | | 一、大会主持人宣布股东会会议开始，介绍参会股东情况及列席会议人员情况 | | | | | 二、推选监票人和计票人 | | | | | 三、宣读并逐项审议各项议案： | | | | | 非累积投票议案 | | | ...

凤 凰 光 学 股 份 有 限 公 司 2025 年第三次临时股东会会议资料 凤凰光学股份有限公司 2025年第三次临时股东会 会议资料 （证券代码：600071） 2025年12月 1 凤 凰 光 学 股 份 有 限 公 司 2025 年第三次临时股东会会议资料 2025年第三次临时股东会议程 | 会议名称 | 凤凰光学股份有限公司 | 2025 | 年第三次临时股东会 | | --- | --- | --- | --- | | 会议召开 方式 | 现场+网络 | 会议召集人 | 公司董事会 | | 会议时间 | 现场会议时间：2025 年 12 月 22 日 | 13 点 30 分 | | | | 网络会议时间：2025 年 12 月 22 | 日上午 9:15 至 12 月 22 | 日下午 15:00 | | 会议地点 | 江西省上饶市凤凰西大道 | 197 | 号本公司四楼会议室 | | 会议主持人 | 公司董事 | 会议法律见证 | 上海市方达律师事务所 | | | 一、大会主持人宣布股东会会议开始，介绍参会股东情况及列席会议人员情况 | | | | | 二、推选监票人和计票人 | | | | | ...

证券之星消息，12月8日，凤凰光学（600071）融资买入1929.24万元，融资偿还1465.53万元，融资净买 入463.71万元，融资余额2.87亿元，近3个交易日已连续净买入累计1481.74万元。 | 交易日 | 融资净买入(元) | | 融资余额(元) | 占流通市值比 | | --- | --- | --- | --- | --- | | 2025-12-08 | | 463.71万 | 2.87亿 | 4.69% | | 2025-12-05 | | 292.79万 | 2.82亿 | 4.70% | | 2025-12-04 | | 725.24万 | 2.79亿 | 4.69% | | 2025-12-03 | | -569.90万 | 2.72亿 | 4.47% | | 2025-12-02 | | 665.63万 | 2.77亿 | 4.57% | | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-08 | 2.87亿 | 463.71万 | 1.64% | | 2025-12-05 | 2.8 ...

Group 1 - The core point of the announcement is the resolutions passed during the 14th meeting of the 9th Board of Directors of Phoenix Optical Co., Ltd, which includes the reappointment of the accounting firm and the expected related transactions for 2026 [2][4][5][24][38]. Group 2 - The Board meeting was held on December 5, 2025, with all 9 directors participating in the voting, complying with relevant regulations [2]. - The proposal to reappoint the accounting firm, Da Xin Certified Public Accountants, was approved unanimously with 9 votes in favor [4][38]. - The expected related transactions for 2026 were also approved with 6 votes in favor, while related directors abstained from voting [5][8]. - A notice for the third extraordinary general meeting of shareholders was approved, scheduled for December 22, 2025 [9][10]. Group 3 - The expected related transactions for 2026 will be submitted for approval at the upcoming extraordinary general meeting, with related shareholders required to abstain from voting [6][14]. - The independent directors have acknowledged and agreed to the expected related transactions, confirming compliance with regulations and fair pricing [14][22]. Group 4 - Da Xin Certified Public Accountants has been proposed for reappointment based on their satisfactory performance in the previous year, with a planned audit fee of 650,000 yuan [24][36]. - The firm has a strong track record, with over 30 years of experience in securities services and a significant number of clients [25][28]. Group 5 - The third extraordinary general meeting will be held on December 22, 2025, with provisions for both on-site and online voting [42][43]. - The meeting will address the proposals that have been previously disclosed, including those requiring abstention from related shareholders [45].

（编辑 丛可心） 证券日报网讯 12月5日晚间，凤凰光学发布公告称，公司拟续聘大信会计师事务所（特殊普通合伙）为 2025年度审计机构，审计费用65万元，其中财务审计费用55万元、内控审计费用10万元，审计费用与上 年持平。 ...

凤凰光学股份有限公司 证券代码：600071 证券简称：凤凰光学 公告编号：2025-034 关于 2026 年日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否需要提交股东会审议：是 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 12 月 5 日，凤凰光学股份有限公司（以下简称"公司"）第九届董 事会第十四次会议以票 6 同意、0 票弃权、0 票反对审议通过了《公司 2026 年度 日常关联交易预计的议案》，关联董事陈宗年先生、徐立兴先生、王俊先生回避 表决，该预案尚需提交公司 2025 年度第三次临时股东会审议，关联股东在股东 会上对该议案回避表决。 公司在召开本次董事会前，就上述日常关联交易事宜与独立董事进行了沟通， 并经独立董事认可。公司独立董事就上述日常关联交易的议案表示同意，并发表 了如下独立意见：公司预计 2026 年度日常关联交易的议案遵守了有关规定，关 联董事回避表决，关联交易公开、公平、公正，定价公允合理。 （二）2025 年度日常关联交 ...